

[182] NOBIO NANOPARTICLES FOR PERMANENT ANTIMICROBIAL PROTECTION

Yoram Ashery¹, ¹ Nobio Ltd

- **Investment Rational**

Infectious diseases account for 15% of global deaths, and proliferation of resistant bacteria vs a shrinking antibiotics pipeline makes a post-antibiotic era – where minor infections and injuries can kill – a realistic scenario for this century. Nobio’s revolutionary nanoparticle technology can transform common materials to antimicrobial, permanently, across many markets, including medical, dental, consumer, industry and more.
- **Business Strategy**

Nobio’s vision is to provide its revolutionary nanoparticle solution to manufacturers of all products that need antimicrobial protection. Nobio is internally developing selected products, for initial launch this year, and collaborating with leading manufacturers for other products and markets. Production is highly scalable, enabling flexible pricing models to maximize the economics.
- **Core Technology**

The core technology are proprietary nanoparticles, comprised of a core to which high concentration of permanently-active antimicrobial groups are covalently bound. Different core materials and functional groups are used for different applications and host-materials, for best performance. The particles are added to the host material during production and once it solidifies will remain there and stay active permanently.
- **Product Profile/Pipeline**

Nobio’s Dental program includes a portfolio of products for treatment and prevention of dental caries (tooth decay), the most common, chronic infection worldwide. The Nobio Medical program develops solutions for preventing infections associated with indwelling devices and implants, which are associated with most hospital acquired infections, costing \$30Bn a year.
- **What's Next?**

First dental products, consisting of a line of adhesives and composite restoratives for treatment of tooth cavities, is expected to be FDA cleared this year, in parallel to completion of a number of clinical trials to support commercial launch. The Medical program will enter clinical trials for first antimicrobial catheters with Nobio’s technology. The Company also expects to enter first industry partnerships this year.